Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
Bristol-Myers Squibb Co BMY
News
Advancing Access to Lung Cancer Care Through Artificial Intelligence Innovation
Bristol Myers Squibb Treatment Meets Primary Endpoint in Phase 3 Trial for Idiopathic Pulmonary Fibrosis
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
Bristol Myers Squibb Says FDA Approves Heart Disease Treatment Camzyos for Pediatric Patients
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Leveraging Brazil's Health Networks for Early Lung Cancer Detection
Transforming Lung Cancer Care & Early Detection in Tanzania
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
How Can Lung Cancer Screening in India Reflect Risk Beyond Smoking?
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
Bristol Myers Squibb Announces Dividend
National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort
United States